Edwards Lifesciences Corporation (EW)

Market Cap	54.98B
Revenue (ttm)	6.14B
Net Income (ttm)	1.41B
Shares Out	602.60M
EPS (ttm)	2.32
PE Ratio	39.32
Forward PE	31.10
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,795,573
Open	90.00
Previous Close	90.25
Day's Range	89.80 - 91.36
52-Week Range	60.57 - 96.12
Beta	1.11
Analysts	Buy
Price Target	94.89 (+4.01%)
Earnings Date	Jul 24, 2024

About EW

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical struct...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Mar 27, 2000
• Employees: 19,800
• Stock Exchange: NYSE
• Ticker Symbol: EW

Financial Performance

In 2023, EW's revenue was $6.00 billion, an increase of 11.56% compared to the previous year's $5.38 billion. Earnings were $1.40 billion, a decrease of -7.85%.

Analyst Forecast

According to 20 analysts, the average rating for EW stock is "Buy." The 12-month stock price forecast is $94.89, which is an increase of 4.01% from the latest price.

Price Target

$94.89

(4.01% upside)

Analyst Consensus: Buy